HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined modality treatment of limited stage small cell carcinoma of the lung.

Abstract
Small cell lung carcinoma comprises approximately 10-20% of all lung cancers. At the time of diagnosis, 20-30% of patients have what is considered limited stage disease. Historically, chemotherapy has been the mainstay of treatment for small cell lung cancer, but more recent evidence from large meta-analyses have established the local control and overall survival advantages conferred by the addition of external beam thoracic radiotherapy in combination with chemotherapy for limited stage disease along with prophylactic cranial irradiation for complete responders. At present, radiotherapy is recommended to commence in concurrentoe with an earlier cycle of chemotherapy. Despite the established role of thoracic radiotherapy combined with chemotherapy for patients with limited stage disease, the optimal radiotherapy dose-fractionation schedule is still undefined. Recent investigational radiotherapy approaches applied to limited stage small cell lung cancer patients include hyperfractionated radiotherapy, dose-escalated daily radiotherapy, and hypofractionation. While several chemotherapy regimens and targeted systemic agents have been investigated in small numbers of small cell lung cancer patients, cisplatin with etoposide remains the current standard chemotherapy regimen for this cancer.
AuthorsDon Yee, Brita Danielson, Wilson Roa
JournalReviews on recent clinical trials (Rev Recent Clin Trials) Vol. 3 Issue 2 Pg. 150-5 (May 2008) ISSN: 1574-8871 [Print] United Arab Emirates
PMID18474026 (Publication Type: Journal Article, Review)
Topics
  • Carcinoma, Small Cell (pathology, therapy)
  • Combined Modality Therapy
  • Humans
  • Lung Neoplasms (pathology, therapy)
  • Neoplasm Staging

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: